Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk

被引:36
|
作者
Kim, Jin You [1 ,2 ]
Kim, Jin Joo [1 ]
Hwangbo, Lee [1 ]
Lee, Ji Won [1 ]
Lee, Nam Kyung [1 ]
Nam, Kyung Jin [3 ]
Choo, Ki Seok [3 ]
Kang, Taewoo [4 ]
Park, Heeseung [4 ]
Son, Yohan [5 ]
Grimm, Robert [6 ]
机构
[1] Pusan Natl Univ Hosp, Med Res Inst, Dept Radiol, Busan, South Korea
[2] Pusan Natl Univ, Dept Radiol, Sch Med, 1-10 Ami Dong, Busan 602739, South Korea
[3] Pusan Natl Univ, Dept Radiol, Yangsan Hosp, Yangsan, South Korea
[4] Pusan Natl Univ Hosp, Busan Canc Ctr, Busan, South Korea
[5] Siemens Healthineers Ltd, Seoul, South Korea
[6] Siemens Healthcare GmbH, Erlangen, Germany
关键词
Diffusion magnetic resonance imaging; Breast neoplasms; Oncotype DX; Recurrence; Biomarkers; ADJUVANT SYSTEMIC THERAPY; ONCOTYPE-DX; AMERICAN-SOCIETY; EARLY-STAGE; TUMOR HETEROGENEITY; GENE-EXPRESSION; COEFFICIENT; CHEMOTHERAPY; WOMEN; SURVIVAL;
D O I
10.1007/s00330-019-06383-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To investigate possible associations between quantitative apparent diffusion coefficient (ADC) metrics derived from whole-lesion histogram analysis and breast cancer recurrence risk in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer who underwent the Oncotype DX assay. Methods This retrospective study was conducted on 105 women (median age, 48 years) with ER-positive, HER2-negative, node-negative breast cancer who underwent the Oncotype DX test and preoperative diffusion-weighted imaging (DWI). Histogram analysis of pixel-based ADC data of whole tumors was performed, and various ADC histogram parameters (mean, 5th, 25th, 50th, 75th, and 95th percentiles of ADCs) were extracted. The ADC difference value (defined as the difference between the 5th and 95th percentiles of ADCs) was calculated to assess intratumoral heterogeneity. Associations between quantitative ADC metrics and the recurrence risk, stratified using the Oncotype DX recurrence score (RS), were evaluated. Results Whole-lesion histogram analysis showed that the ADC difference value was different between the low-risk recurrence (RS < 18) and the non-low-risk recurrence (RS >= 18; intermediate to high risk of recurrence) groups (0.600 x 10(-3) mm(2)/s vs. 0.746 x 10(-3) mm(2)/s, p < 0.001). Multivariate regression analysis demonstrated that a lower ADC difference value (< 0.559 x 10(-3) mm(2)/s; odds ratio [OR] = 5.998; p = 0.007) and a small tumor size (<= 2 cm; OR = 3.866; p = 0.012) were associated with a low risk of recurrence after adjusting for clinicopathological factors. Conclusions The ADC difference value derived from whole-lesion histogram analysis might serve as a quantitative DWI biomarker of the recurrence risk in women with ER-positive, HER2-negative, node-negative invasive breast cancer.
引用
收藏
页码:66 / 76
页数:11
相关论文
共 50 条
  • [1] Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk
    Jin You Kim
    Jin Joo Kim
    Lee Hwangbo
    Ji Won Lee
    Nam Kyung Lee
    Kyung Jin Nam
    Ki Seok Choo
    Taewoo Kang
    Heeseung Park
    Yohan Son
    Robert Grimm
    European Radiology, 2020, 30 : 66 - 76
  • [2] Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer
    Rakha, Emad A.
    Agarwal, Devika
    Green, Andrew R.
    Ashankyty, Ibraheem
    Ellis, Ian O.
    Ball, Graham
    Alaskandarany, Mohammed A.
    HISTOPATHOLOGY, 2017, 70 (04) : 622 - 631
  • [3] Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer
    Alshamsan, Bader
    Alshibany, Aisha
    Elshenawy, Mahmoud A.
    Badran, Ahmed
    Elhassan, Tusneem
    Ajarim, Dahish
    Alsayed, Adher
    Suleman, Kausar
    Al-Tweigeri, Taher
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 9411 - 9420
  • [4] Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score
    Meisel, Jane
    Zhang, Chao
    Neely, Cameron
    Menduza, Pia
    You, Shuo
    Han, Tatiana
    Liu, Yuan
    Sahin, Aysegul A.
    O'Regan, Ruth
    Li, Xiaoxian
    CLINICAL BREAST CANCER, 2018, 18 (05) : 347 - 352
  • [5] Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer
    Kim, Hee Jeong
    Choi, Woo Jung
    Kim, Hak Hee
    Cha, Joo Hee
    Shin, Hee Jung
    Chae, Eun Young
    CLINICAL IMAGING, 2021, 75 : 131 - 137
  • [6] Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations
    Nagaraj, Gayathri
    Ma, Cynthia X.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (03): : 246 - 251
  • [7] Prediction of the MammaPrint Risk Group Using MRI Features in Women With Estrogen Receptor-Positive, HER2-Negative, and 1 to 3 Node-Positive Invasive Breast Cancer
    Kim, Hee Jeong
    Choi, Woo Jung
    Cha, Joo Hee
    Shin, Hee Jung
    Chae, Eun Young
    Kim, Hak Hee
    CLINICAL BREAST CANCER, 2024, 24 (02) : e80 - e90
  • [8] Association of mammography and ultrasound features with MammaPrint in patients with estrogen receptor-positive, HER2-negative, node-positive invasive breast cancer
    Choi, Woo Jung
    Sim, Hayan
    Kim, Hee Jeong
    Cha, Joo Hee
    Shin, Hee Jung
    Chae, Eun Young
    Kim, Hak Hee
    ACTA RADIOLOGICA, 2021, 62 (12) : 1592 - 1600
  • [9] Ki-67 index value and progesterone receptor status can predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor-positive and HER2-negative tumors
    Arima, Nobuyuki
    Nishimura, Reiki
    Osako, Tomofumi
    Okumura, Yasuhiro
    Nakano, Masahiro
    Fujisue, Mamiko
    Nishiyama, Yasuyuki
    Toyozumi, Yasuo
    ONCOLOGY LETTERS, 2019, 17 (01) : 616 - 622
  • [10] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26) : 2557 - 2570